Clinical effect of montelukast sodium combined with inhaled corticosteroids in the treatment of OSAS children

Da-Zhi Yang, MD, Jia Liang, MD, Feng Zhang, MD, Hong-Bing Yao, MD, Yan Shu, MD∗

Abstract
This study was designed to investigate the clinical effect of montelukast sodium combined with inhaled corticosteroids in the treatment of children with obstructive sleep apnea syndrome (OSAS).

One hundred ninety-five children were enrolled and divided into 3 groups: groups A, B, and C; the group A (oral use of montelukast sodium), group B (nasal spray of mometasone furoate), and group C (oral use of montelukast sodium + nasal spray of mometasone furoate). Telephone questionnaire surveys were carried out. Polysomnography monitoring was performed and lateral x-ray radiographs of the cervical spine were taken before treatment and at 12 weeks after treatment. The improvement of clinical symptoms after treatment and its effective rate were analyzed. The difference in clinical characteristics between groups C1 and C2 was analyzed.

In the 3 groups, clinical symptoms improved at 12 weeks after treatment compared with before (P < .05 or P < .01). Apnea-hypopnea index value decreased (P < .05) and minimal SaO2 increased (P < .05), while adenoidal/nasopharyngeal ratio was reduced (P < .05). Compared with groups A and B, group C had a shortened response duration of snoring, apnea, and restless sleep (P < .05). Differences in the response duration of buccal respiration and hyperhidrosis were not statistically significant (P > .05). The total effective rate was higher in group C than in A and B (P < .05), while the differences in all indices between groups A and B were not statistically significant (P > .05). The difference in the grade of the size of the tonsil between groups C1 and C2 was statistically significant (P < .05).

The total effective rate of the combined treatment was higher than that of the single use of any of the 2 drugs, which allowed the rapid relief of symptoms. Drug treatment may have a poor curative effect in the treatment of OSAS patients with ≥ grade 3 tonsil hypertrophy.

Abbreviations: ICS = inhaled corticosteroids, OM = oral montelukast sodium, OSAS = obstructive sleep apnea syndrome, PSG = polysomnography, T&A = adenotonsillectomy.

Keywords: montelukast sodium, obstructive sleep apnea syndrome, sleep, snoring

1. Introduction
Obstructive sleep apnea syndrome (OSAS) in children is a common disease in pediatric otorhinolaryngology. Apnea and insufficient ventilation caused by upper airway collapse and obstruction during sleep may lead to clinical symptoms such as snoring, sleep disorder, frequent decrease in blood oxygen saturation, and daytime sleepiness, which seriously affects children’s health. OSAS may occur in all age stages, and has an incidence of approximately 1% to 5% in all children. The pathogenic peak occurs between 2 and 8 years old.[1–4] OSAS without treatment can lead to severe related diseases, mainly affecting neurocognitive, behavioral, and cardiovascular systems.[5] Long-term chronic hypoxia is also a risk factor for adulthood cardiovascular disease. Adult OSAS is often related to obesity and other factors. However, the pathogenesis of children OSAS is complex, and is a result of the synthetic action of anatomical structural and neuromuscular abnormalities.[6] The most important factor is upper airway stenosis caused by tonsil and adenoid hypertrophy. Therefore, tonsillectomy and/or adenoidectomy are the main methods for the treatment of OSAS in children. However, some children are very young or the symptoms are mild. Hence, it remains unknown whether surgery is appropriate for these children, which is controversial in clinic.

In recent years, research on the inflammatory mechanisms of OSAS in children has provided a new idea for nonoperative treatment with anti-inflammatory drugs, such as montelukast sodium or inhaled corticosteroids (ICS). Studies have revealed that abundant cysteinyl leukotriene receptors-1 and glucocorticoid receptor-α were detected from tonsil and adenoid tissues in OSAS children.[7,8] Studies have reported that after ICS, or oral montelukast sodium (OM), or the combined treatment of ICS and OM, sleep-disordered breathing improved, and adenoid volume...
decreased in children with mild OSAS. However, it remains to be determined which of these 3 treatment methods is better.

The purpose of this study was to compare the clinical efficacy of ICS and OM through a randomized controlled study, to seek for a more suitable clinical drug treatment.

2. Materials and methods

This study was conducted in accordance with the Declaration of Helsinki. This study was conducted with approval from the Ethics Committee of our hospital. Written informed consent was obtained from all participants.

2.1. Data of objects

From September 2011 to September 2015, children diagnosed with OSAS in the special section of the ear, nose, and throat (ENT) Departments of Otolaryngology, Children’s Hospital of Chongqing Medical University were enrolled into this study using a random number table. Inclusion criteria: children diagnosed with OSAS (mild) by polysomnography (PSG) monitoring; children who were unwilling to undergo surgical treatment; children without history of tonsilllectomy and/or adenoidectomy; children with symptoms that lasted for more than 12 months. Exclusion criteria: children with tonsil hypertrophy alone; children with a history of allergic rhinitis or asthma; children with a history of superior respiratory tract infections 2 weeks before the treatment, or a history of the use of antibiotics within 4 weeks; children with a history of related diseases: nasal disease (a continuous history of rhinitis or sinusitis attacks), nasal anatomic anomalies (nasal septum flunk-curve), cranial and facial deformity, cardiovascular disease, immunodeficiency disease, hormone, or histamine allergy, etc.

2.2. Grouping of the objects

These subjects were divided into 3 groups: group A (oral use of montelukast sodium), group B (nasal spray of mometasone furoate), and group C (oral use of montelukast sodium + nasal spray of mometasone furoate).

2.3. Ethical support

The 2 drugs used in this study (OM and ICS) are both clinically safe drugs. OM is a commonly used drug in the treatment of asthma, while ICS is a first-line drug used in the treatment of allergic rhinitis. These 2 drugs have not been found to induce any significant side effects in clinic. Furthermore, it has been reported in the literature that these 2 drugs are also being used for the treatment of children with OSAS abroad. The present study was approved by the Ethics Committee of the Affiliated Children’s Hospital of Chongqing Medical University, China. For the follow-up and monitoring of children during treatment, agreement and informed consent were provided by the guardians.

2.4. Research methods

2.4.1. Method of administration for subjects. Group A: OM (4 mg for children < 6 years old and 5 mg for children ≥ 6 years old), once a night, for 12 weeks.

Group B: mometasone furoate nasal spray once a morning, a spray for each nasal cavity (50 μg), for 12 weeks.

Group C: OM (4 mg for children < 6 years old and 5 mg for children ≥ 6 years old), once a night; and mometasone furoate nasal spray once a morning, a spray for each nasal cavity (50 μg), for 12 weeks.

2.4.2. Clinical observation indices.

(1) Clinical symptoms

A. Face-to-face questionnaire survey before treatment and a telephone questionnaire survey during treatment (after the beginning of treatment, once a week; and the results were recorded) was performed.

B. Clinical symptom scoring (0–4 points): 0 point = never; 1 point = once in a while; 2 points = sometimes; 3 points = often; 4 points = continuous.

C. Tonsil size scoring (0–4 points): 0 point = the tonsil cannot be felt; 1 point = the tonsil is located in the tonsillar fossa; 2 points = the tonsil lies beyond the tonsillar fossa, but does not exceed the palatal midline; 3 points = the tonsil exceeds the palatal midline, but the bilateral tonsils do not contact with each other; 4 points = bilateral tonsils closely contact with each other.

2.5. Statistical methods

Data were statistically analyzed using statistical software SPSS 16.0. Measurement data were expressed as mean ± standard deviation (± SD). Comparison between 2 groups was conducted using t test, comparison of mean data among multiple samples was conducted using analysis of variance, comparison of rates among multiple samples was conducted using χ² test, and P < .05 was considered statistically significant.

3. Results

3.1. Basic information of subjects

A total of 195 children, who saw a doctor in the special section of the ENT Department of our hospital and were diagnosed with mild OSAS, were enrolled into this study. These children were randomly divided into 3 groups: groups A, B, and C (n = 65). Among these children, 4 and 8 children in groups B and C, respectively, withdrew from the study, because they did not insist on regular medication during the treatment, or was lost to follow-up. Differences in gender proportion, age, past history, signs, and PSG monitoring data among these groups were not statistically significant (P > .05, Tables 1 and 2).

3.2. Changes in clinical characteristics and PSG monitoring data before and after treatment

Finally, 65 children in group A, 61 children in group B and 57 children in group C completed the 12-week course of treatment and follow-up. Results are shown in Table 2. Clinical symptoms...
such as snoring, buccal respiration, restless sleep, hyperhidrosis, and apnea improved in children in the 3 groups after treatment, compared with before treatment ($P < 0.05$ or $P < 0.01$). After the end of treatment, the second PSG monitoring revealed that AHI decreased ($P < 0.05$) and minimal SaO2 increased ($P < 0.05$) in children in the 3 groups. After the end of the treatment, lateral X-ray radiographs of the cervical spine were taken for the second time; and the radiographs revealed that the adenoidal/nasopharyngeal ratio (A/N ratio) decreased ($P < 0.05$).

### 3.3. Comparison of the response duration of clinical symptoms and the total effective rate in children after treatment

Results are shown in Table 3. The difference in response duration of children between groups A and B was not statistically significant ($P > 0.05$). Compared with groups A and B, response duration of snore, apnea, and restless sleep were shorter in group C; and the differences were statistically significant ($P < 0.05$). Furthermore, differences in the response duration of buccal respiration and hyperhidrosis were not statistically significant ($P > 0.05$). The total effective rate was higher in children in group C compared with children in groups A and B, and the differences were statistically significant ($P < 0.05$). The difference in the total effective rate between groups A and B was not statistically significant ($P > 0.05$).

### 3.4. Comparison of clinical characteristics between the effective group (group C1) and ineffective group (group C2) within group C

After the end of treatment, children in group C were further divided into 2 groups: effective group (group C1) and ineffective group (group C2); and the clinical characteristics between these 2

### Table 1

| Basic information of subjects (n = 183). |
|-----------------------------------------|
|                                         |
| **A group** | **B group** | **C group** | **P group** |
| Cases | 65 | 61 | 57 |
| Gender (male, %) | 37 (58.7%) | 32 (54.2%) | 30 (54.5%) | NS |
| Age (y) | 42 ± 1.3 | 40 ± 1.7 | 3.9 ± 1.6 | NS |
| BMI (z score) | 0.81 ± 1.02 | 0.79 ± 1.13 | 0.71 ± 1.30 |
| Allergic history, % | 3% | 5% | 5% | NS |
| Tonsil hypertrophy with adenoidal hypertrophy, % | 50.4% | 57.6% | 52.9% | NS |
| Only adenoidal hypertrophy, % | 49.6% | 42.4% | 47.1% | NS |
| A/N | 0.73 ± 0.08 | 0.71 ± 0.01 | 0.75 ± 0.02 | NS |
| Tonsillar size | 2.22 ± 0.13 | 2.28 ± 0.15 | 2.15 ± 0.28 | NS |
| AHI | 7.25 ± 1.52 | 6.1 ± 1.28 | 6.9 ± 1.52 | NS |
| Minimal SaO2 | 90.7 ± 2.5 | 89.25 ± 2.01 | 90.16 ± 2.01 | NS |

All data are expressed as mean ± SD. A/N = apnea/hypopnea index, NS = not significant.

### Table 2

| Symptoms and polysomnographic characteristics in groups A, B, and C before and after treatment ($X ± s$). |
|---------------------------------------------------------------|
| **A group (n = 65)** | **B group (n = 61)** | **C group (n = 57)** |
| Pre | Post | $P$ | Pre | Post | $P$ | Pre | Post | $P$ |
| Snoring | 3.46 ± 1.55 | 1.29 ± 0.26 | <.01 | 3.23 ± 1.41 | 1.1 ± 0.37 | <.01 | 3.99 ± 1.73 | 1.51 ± 0.22 | <.01 |
| Mouth breathing | 3.27 ± 0.79 | 2.03 ± 0.62 | <.05 | 3.22 ± 0.56 | 2.15 ± 0.4 | <.05 | 3.42 ± 0.43 | 2.06 ± 0.3 | <.05 |
| Restless sleep | 3.04 ± 0.91 | 1.14 ± 0.15 | <.05 | 3.13 ± 0.62 | 1.09 ± 0.2 | <.05 | 3.11 ± 0.9 | 1.07 ± 0.25 | <.05 |
| Sweating | 0.98 ± 0.7 | 0.76 ± 0.00 | <.01 | 0.79 ± 0.01 | 0.56 ± 0.1 | <.05 | 0.76 ± 0.2 | 0.65 ± 0.4 | <.05 |
| A/N ratio | 0.32 ± 0.10 | 0.28 ± 0.07 | <.05 | 0.27 ± 0.07 | 0.25 ± 0.03 | <.05 | 0.27 ± 0.07 | 0.25 ± 0.03 | <.05 |
| Tonsillar size | 2.22 ± 0.13 | 2.05 ± 0.1 | NS | 2.25 ± 0.15 | 2.21 ± 0.17 | NS | 2.19 ± 0.29 | 2.15 ± 0.15 | NS |
| AHI (h TST) | 7.25 ± 1.52 | 1.3 ± 0.68 | <.01 | 6.1 ± 1.13 | 1.2 ± 1.05 | <.01 | 6.9 ± 1.52 | 1.61 ± 1.3 | <.01 |
| Minimal SaO2 | 90.7 ± 2.5 | 90.25 ± 2.01 | <.05 | 90.25 ± 2.01 | 90.25 ± 2.01 | <.05 | 90.16 ± 2.01 | 94.8 ± 1.2 | <.05 |

Measurements were taken at study entry (pre) and after 12 weeks of treatment (post). A/N ratio = adenoidal/nasopharyngeal ratio, AHI = apnea/hypopnea index, NS = not significant, TST = total sleep time.

### Table 3

| Results of questionnaire and effective rate in three groups after treatment ($X ± s$, d). |
|---------------------------------------------------------------|
| **Group** | **Snoring** | **Mouth breathing** | **Sweating** | **Witnessed apnea** | **Restless sleep** | **Total effective rate (%)** |
| A | 75.2 ± 5.65 | 82.14 ± 3.2 | 67.25 ± 3.92 | 30.58 ± 2.7 | 30.1 ± 2.9 | 62.7 |
| B | 70.22 ± 4.16 | 79.11 ± 4.15 | 70.3 ± 3.32 | 28.13 ± 2.08 | 33.0 ± 2.64 | 63.1 |
| C | 47.55 ± 2.5 | 80.01 ± 4.7 | 66.5 ± 2.1 | 14.63 ± 3.11 | 14.17 ± 2.03 | 73.7 |

$d =$ days, symptoms disappeared (or remission) time. $^{*}$Significant difference between groups A and C ($P < 0.05$).

$^1$Significant difference between B and C ($P < 0.05$).

$^2$ Significant difference between groups A and C ($P < 0.05$).
groups were further analyzed. Results are shown in Table 4. Differences in age, gender proportion, A/N ratio, AHI, and minimal SaO₂ between groups C1 and C2 were not statistically significant (P > .05). However, the difference in tonsil size between these 2 groups was statistically significant (P < .05).

4. Discussion

This study revealed that at 12 weeks after OM or ICS treatment, respiratory disorders in part of the children with mild OSAS could be alleviated, and the effective rate was 62.4% and 63.1%, respectively. The difference between these 2 treatments was not statistically significant. At 12 weeks after the combined treatment of OM and ICS, the effective rate (73.7%) was significantly higher than that of the single-drug treatment; and the response durations of snoring, apnea and restless sleep were shorter than those of single-drug treatment.

A recent study revealed that nasal and oropharynx oropharyngeal mucosal inflammation in children with OSAS may be related to hyperplasia and hypertrophy of the adenoid and tonsil, and may play important roles in the pathogenesis of sleep-disordered breathing in children.[13] However, the systemic application of corticosteroids has no effect in the treatment of OSAS.[14] A number of studies have revealed that[10,15] the expression of the glucocorticoid receptor in the upper airway lymphoid tissue in children with OSAS increased. The volume of expression of the glucocorticoid receptor and glucocorticoid receptor–

References

[1] Kaditis AG, Finder J, Alexopoulos EI, et al. Sleep-disordered breathing in 3,680 Greek children. Pediatr Pulmonol 2004;37:499–509.
[2] Montgomery-Downs HE, O’Brien LM, Holbrook CR, et al. Snoring and sleep-disordered breathing in young children: subjective and objective correlates. Sleep 2004;27:87–94.
[3] Li AM, So HK, Au CT, et al. Epidemiology of obstructive sleep apnoea syndrome in Chinese children: a two-phase community study. Thorax 2010;65:991–7.
[4] Marcus CL, Brooks IJ, Draper KA, et al. American Academy of PediatricsDiagnosis management of childhood obstructive sleep apnea syndrome. Pediatrics 2012;130:e714–55.
[5] Goldbart AD, Mager E, Veling MC, et al. Neurotrophins and tonsillar hypertrophy in children with obstructive sleep apnea. Pediatr Res 2007;62:489–94.
[6] Marcus CL, McColley SA, Carroll JL, et al. Upper airway collapsibility in children with obstructive sleep apnea syndrome. J Appl Physiol (1985) 1994;77:918–24.
[7] Kaditis AG, Ioannou MG, Chaidas K, et al. Cysteinyl leukotriene receptors are expressed by tonsillar T cells of children with obstructive sleep apnea. Chest 2008;133:924–31.
[8] Goldbart AD, Veling MC, Goldman JS, et al. Glucocorticoid receptor subunit expression in adenotonsillar tissue of children with obstructive sleep apnea. Pediatr Res 2005;57:232–6.
[9] Kheirandish-Gozal L, Gozal D. Intranasal budesonide treatment for children with mild obstructive sleep apnea syndrome. Pediatrics 2008;122:e149–55.
[10] Berlucchi M, Salsi D, Valetti L, et al. The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics 2007;119:e1392–7.

[11] Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics 2012;130:e575–80.

[12] Kheirandish-Gozal L, Bhattacharjee R, Bandla HP, et al. Anti-inflammatory therapy outcomes for mild OSA in children. Chest 2014;146:88–95.

[13] Goldbart AD, Krishna J, Li RC, et al. Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome. Chest 2006;130:143–8.

[14] Al-Ghamdi SA, Manoukian JJ, Morielli A, et al. Do systemic corticosteroids effectively treat obstructive sleep apnea secondary to adenotonsillar hypertrophy? Laryngoscope 1997;107:1382–7.

[15] Demain JG, Goetz DW. Pediatric adenoidal hypertrophy and nasal airway obstruction: reduction with aqueous nasal beclomethasone. Pediatrics 1995;95:55–64.

[16] Goldbart AD, Goldman JL, Veling MC, et al. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med 2005;172:364–70.

[17] Kheirandish L, Goldbart AD, Gozal D. Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children. Pediatrics 2006;117:e61–6.